Clinical Trial

TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma

Study acronym: TALASUR
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main objectif is to determine the efficacy of a maintenance treatment combining Talazoparib and Avelumab after platinum-based chemotherapy in patients with locally advanced/metastatic urothelial carcinoma.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-12-16; most recent amendment 2025-09-17.
Status change: Not Yet Recruiting → Recruiting 2021-06-02
Trial Details
NCT Number NCT04678362
Lead Sponsor Centre Francois Baclesse
Collaborators: Pfizer
Conditions Urothelial Carcinoma
Enrollment 50 participants
Start Date 2021-06-01
Primary Completion 2023-07-28 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-22